- Home
- ZTR vs RXST Comparison
ZTR vs RXST Comparison
Compare ZTR & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZTR | RXST |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.2M | 305.0M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZTR | RXST |
|---|---|---|
| Price | $6.72 | $6.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.78 |
| AVG Volume (30 Days) | 196.7K | ★ 683.9K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.22 | $5.90 |
| 52 Week High | $7.11 | $17.49 |
Technical Indicators
Market Signals| Indicator | ZTR | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 35.74 |
| Support Level | $6.71 | N/A |
| Resistance Level | $6.92 | $9.11 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 55.92 | 23.28 |
Price Performance
Historical ComparisonAbout ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.